Mesoblast Limited (MESO)
NASDAQ
$15.12−$0.3650 (−2.36%) on the dayAs of the close; data may be delayed.
MESO price, last 12 months
Key stats
- Previous close
- $15.48
- Open
- $15.30
- Day range
- $15.10 – $15.35
- 52-week range
- $13.05 – $21.50
- Volume
- 110.8K
- Avg volume (20 days)
- 194.5K
- Market cap
- $2.0B
Performance
1W−0.1%
1M−10.2%
3M+14.6%
6M+1.7%
YTD−16.2%
1Y−7.0%
vs S&P 500, 1Y−23.8 pts
Technicals and fundamentals
About Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
- Listed on
- NASDAQ
- Market cap
- $2.0B